{"organizations": [], "uuid": "2250e764aca60b435887d2d94c62ac587aa8101c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/12", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-oncomed-pharmaceuticals-to-report-first-quarter-2018-financial-results-and-operational-highlights-on-may-8th-2018.html", "country": "US", "domain_rank": 767, "title": "OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-05-01T15:30:00.000+03:00", "replies_count": 0, "uuid": "2250e764aca60b435887d2d94c62ac587aa8101c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-oncomed-pharmaceuticals-to-report-first-quarter-2018-financial-results-and-operational-highlights-on-may-8th-2018.html", "ord_in_thread": 0, "title": "OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "redwood city", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "oncomed pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "celgene corporation", "sentiment": "none"}, {"name": "oncomed pharmaceuticals oncomed pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "REDWOOD CITY, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8 th , 2018. OncoMed will not be conducting a conference call in conjunction with this earnings release.\nAbout OncoMed Pharmaceuticals\nOncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com .\nInvestor Relations Contact:\nMatthew Beck\nSolebury Trout\nmbeck@troutgroup.com\n(646) 378-2933\nSource:OncoMed Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/250c7064-4e3c-489e-ae1b-9daf1a471d06", "https://www.globenewswire.com/Tracker?data=Q0j9wc2PplNUc-1uapSJEy-bUcjed4_f7lz4eGHEx1YIzJeiE69L3xXqGVJvy1Ju_FAy2Nf5CJS-eG15cO7Oug=="], "published": "2018-05-01T15:30:00.000+03:00", "crawled": "2018-05-01T19:13:11.027+03:00", "highlightTitle": ""}